Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.71 |
| ▸ | NT5C2 | P49902 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9230081 | 0.83 | BRD4 (1.00) | BRD4NT5C2CREBBPNPC1RAB9A | |
| SCHEMBL18941360 | 0.82 | BRD4 (0.56) | BRD4NPC1RAB9AKMT2ATP53 | |
| SCHEMBL18941369 | 0.74 | ADORA3 (0.44) | BRD4NPC1RAB9AKMT2ATP53 | |
| SCHEMBL9230078 | 0.72 | BRD4 (0.68) | BRD4NPC1RAB9AKMT2ATP53 | |
| SCHEMBL11831247 | 0.71 | NPC1 (0.68) | NPC1RAB9AKMT2ATP53ALOX15 | |
| SCHEMBL13667383 | 0.71 | BRD4 (0.57) | BRD4NPC1RAB9AKMT2ATP53 | |
| SCHEMBL545883 | 0.69 | NPC1 (0.38) | BRD4NT5C2NPC1RAB9ATP53 | |
| SCHEMBL546075 | 0.68 | XDH (0.53) | NPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL5860314 | 0.68 | POLB (0.45) | BRD4NPC1RAB9AKMT2ATP53 | |
| SCHEMBL11781274 | 0.66 | HPGDS (0.66) | BRD4NPC1RAB9AKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143038-B1 | PEPTIDE-NUCLEIC ACID-MONOMERS AND -OLIGOMERS | UGISENSE AG (DE) | 2018-08-01 | — | — | EP | claimed |
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | UGISENSE AG (DE) | 2017-06-15 | — | — | US | claimed |
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | UGISENSE AG (DE) | 2017-06-15 | — | — | US | disclosed |
| US-7105648-B1 | Oligomers substituted by phosphite acid ester, phosphonic acid or carbaborane functions and the corresponding PNA monomers | UGICHEM GMBH (AU) | 2006-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | DTYMK, POLM, PNKP | BRD4 4676/4885NT5C2 250/4885CREBBP 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.